# China NMPA Product Recall - Nucleic acid extraction reagents / Nucleic acid extraction or purification reagents

Source: https://www.keypedia.com/records/china_product_recall/biomerieux-sa/59f29a01-9a0e-4bf3-b100-77530793e1fa
Source feed: China

> China NMPA product recall for Nucleic acid extraction reagents / Nucleic acid extraction or purification reagents by bioMerieux, SA published January 13, 2017. Recall level: Level III. bioMérieux Diagnostics (Shanghai) Co., Ltd., operating under the regulatory framework of the Nationa

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: bioMérieux Diagnostics Products (Shanghai) Co., Ltd. is voluntarily recalling nucleic acid extraction reagents/nucleic acid extraction or purification reagents.
- Company Name: bioMerieux, SA
- Publication Date: 2017-01-13
- Product Name: Nucleic acid extraction reagents / Nucleic acid extraction or purification reagents
- Recall Level: Level III
- Recall Reason: Subsequent stability studies revealed deviations in the test results of certain batches of MagSIL.
- Discovering Company: bioMérieux Diagnostics Products (Shanghai) Co., Ltd.
- Manufacturing Company: bioMerieux, SA
- Summary: bioMérieux Diagnostics (Shanghai) Co., Ltd., operating under the regulatory framework of the National Medical Products Administration (NMPA), initiated an extended Level III voluntary recall of its Nucleic Acid Extraction Reagents/Nucleic Acid Extraction or Purification Reagents, publicized on January 13, 2017. This action follows an initial recall in September 2016. The primary concern stems from deviations identified in stability studies of certain batches of magnetic beads (MagSIL strain) within these reagents. These deviations potentially cause delayed Ct values in downstream PCR and RT-PCR analyses when the reagents are used with the NucliSENS easyMAG Nucleic Acid Extractor. Such issues could lead to false negative or invalid results during RNA extraction from human samples. While bioMérieux noted that overall product performance was unaffected for customers using their downstream detection reagents, the company took precautionary measures. The affected products, specifically Nuclisens miniMAG extraction reagents (catalog numbers 280133 and 200293), were primarily utilized in mainland China for data analysis or research by entities like disease control centers, not for clinical diagnostics. Required actions include comprehensive customer notification letters outlining necessary steps and an ongoing re-investigation into the product concerns.

Company: https://www.keypedia.com/companies/biomerieux-sa/3062dae8-14a1-439b-b281-c6f0ca786f03